Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bioasis Technologies's enterprise value is $0.00 Mil.
Bioasis Technologies's EBITDA for the trailing twelve months (TTM) ended in Nov. 2022 was $-2.42 Mil. Therefore, Bioasis Technologies's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Bioasis Technologies's EV-to-EBITDA or its related term are showing as below:
BIOAF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 13.39 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioasis Technologies's PE Ratio (TTM) for today is calculated as:
Bioasis Technologies's share price for today is $0.0001.
Bioasis Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.025.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bioasis Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOAF vs VRTX, REGN, SGEN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Bioasis Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioasis Technologies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioasis Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bioasis Technologies's EV-to-EBITDA falls into.
Bioasis Technologies's current Enterprise Value is $0.00 Mil.
Bioasis Technologies's EBITDA for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioasis Technologies (BIOAF) has a EV-to-EBITDA of 0.00 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bioasis Technologies.
Is Bioasis Technologies' EV-to-EBITDA too high?
Bioasis Technologies' current EV-to-EBITDA is 0.00. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' EV-to-EBITDA compare to VRTX and REGN?
Bioasis Technologies' EV-to-EBITDA of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bioasis Technologies. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioasis Technologies's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current EV-to-EBITDA is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score
Get the complete analysis for BIOAF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOAF has been successfully added to your 
